Overview
Suvorexant, marketed under the brand name Belsomra, is a first-in-class dual orexin receptor antagonist (DORA) approved by the FDA in 2014 for the treatment of insomnia. Unlike traditional sedatives (e.g., benzodiazepines), it targets the orexin neuropeptide system, which plays a key role in wakefulness regulation. By selectively blocking OX1R and OX2R receptors, suvorexant promotes sleep onset and maintenance without broadly suppressing central nervous system activity. Developed by Merck & Co., suvorexant represents a mechanistically distinct approach to insomnia therapy. Its clinical efficacy is demonstrated in reducing sleep latency and improving sleep maintenance, particularly in adults with chronic insomnia. The drug is typically administered in 5-20 mg doses, adjusted based on patient response and tolerability.
Physical and Chemical Properties
Suvorexant is a white to off-white crystalline powder with a molecular weight of 450.92 g/mol. Its chemical structure includes a triazole moiety and a chlorobenzoxazole group, contributing to its high affinity for orexin receptors. The compound melts at approximately 180-185°C and exhibits moderate solubility in dimethyl sulfoxide (DMSO) but limited solubility in aqueous solutions. Stability studies indicate that suvorexant degrades under prolonged exposure to light, heat, or humidity. It is sensitive to oxidative conditions, requiring inert atmosphere storage for long-term preservation. Analytical methods such as HPLC and mass spectrometry are commonly used for purity verification, with pharmaceutical-grade material requiring ≥98% purity.
Main Applications
Suvorexant is exclusively used for treating insomnia, specifically addressing difficulties with sleep onset and/or maintenance. Clinical trials have shown its effectiveness in reducing nighttime awakenings and improving total sleep time, with effects lasting up to 6-8 hours post-dose. It is prescribed for adults, typically at 10-20 mg taken orally before bedtime. Beyond primary insomnia, research explores suvorexant's potential in circadian rhythm disorders and jet lag management. However, off-label uses remain investigational. The drug is contraindicated in narcolepsy due to its wakefulness-suppressing mechanism. Formulations are limited to oral tablets, though compounded preparations may exist for specific patient needs.
Safety and Storage
Suvorexant carries a Boxed Warning for impaired alertness and complex sleep behaviors (e.g., sleep-driving). Patients must avoid alcohol and other CNS depressants. Common side effects include daytime drowsiness, dizziness, and dry mouth. Rare but severe reactions include temporary paralysis during sleep (sleep paralysis) or hallucinations. Proper storage requires protection from light and moisture at 2-8°C in sealed containers. Bulk pharmaceutical material should be handled in controlled environments to prevent degradation. Stability data typically support a 24-month shelf life when stored correctly. Disposal must follow hazardous waste protocols due to potential environmental persistence.
B2B Procurement Guide
Pharmaceutical manufacturers sourcing suvorexant must prioritize GMP-certified suppliers with documented quality control processes. Key procurement criteria include batch-specific Certificates of Analysis (COA), residual solvent profiles, and impurity identification (e.g., USP/EP monographs). Regulatory documentation (DMF, CEP) is essential for global supply chains. Pricing varies by quantity and purity, with kilogram-scale purchases commonly negotiated at $200-$400 per gram. Lead times average 8-12 weeks due to synthesis complexity. Auditing suppliers for scale-up capability and regulatory compliance (FDA/EMA/PMDA) is recommended. Alternatives like Lemborexant may be evaluated for comparative cost-effectiveness.
Related Manufacturers
- 主营：凉味剂、除氧剂、防老剂、柔顺剂、抗氧剂、保湿剂、珠光片、丙二酸钠、丙烯酸锌、氟甲基苯、异辛酸锌、十二烷基、2四油酸酯、优级福美钠、农药中间体、彩色显影剂、氢化蓖麻油、高效阻聚剂、固化促进剂、甲基乙二醇、优级有机硅、缓蚀阻垢剂、复合型乳液、氧基铝酸酯、三氟甲氧基